---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060806"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:01:49.390810+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics Q1 net loss $5.6M; cash $1.3M; merges with Peak Bio, cuts 67% workforce

## Summary
- Q1 net loss $5.6M vs net income $1.0M in Q1 2023; adjusted net loss $6.2M excluding warrant gains.
- Cash $1.3M as of March 31, 2024; issued $1M in unsecured convertible notes from CEO and Chairman.
- Entered all-stock merger with Peak Bio, expected close Q3 2024; combined company will trade as AKTX.
- Appointed Samir R. Patel as interim CEO; suspended HSCT-TMA program.
- Reduced workforce by ~67% as part of restructuring to cut costs.

## SEC filing metadata
- accession: 0000950170-24-060806
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024060806/0000950170-24-060806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024060806/aktx-20240516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060806
- JSON: https://secwatch.observer/filing/0000950170-24-060806.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060806.txt

## Key facts
- Earnings Releases
  Akari Therapeutics Plc reported the first quarter ended March 31, 2024 results: net income Net loss was approximately $5.6 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss was approximately $5.6 million
  - Result: reported results
  source text: Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter ended March 31, 2024 as well as recent company highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024060806/0000950170-24-060806-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.